Genmab — December 2020
-
let me repost this FierceBiotech article- ASH: J&J links subcut BCMA bispecific to 73% response rate, plots aggressive investment https://www.fiercebiotech.com/biotech/ash-j-j-links-subcut-bcma-bispecific-to-73-response-rate-plots-aggressive-investment ; interesting on Dara / T&T concerns
-
"Initially, J&J, like its rivals, is going after heavily pretreated patients but it plans to move into earlier lines of therapy. J&J is testing the bispecific in combination with its anti-CD38 blockbuster Darzalex and has aspirations to establish it as a maintenance therapy and in the smoldering myeloma space."
-
Thanks E L. What confuse me with 48-60 mg group (91% ORR), if they cut out 60 mg ORR drops, but there is on data on patients only receiving 48 mg? There is a group 12 - 48 mg. Which of cource has lover ORR...
-
Talquetamab may be even more interesting than Teclistamab, because JNJ is first mover in a less crowded market.
-
less crowded target.
-
Begge grupper er heavily pretreated
-
Jeg ikke læst alle fodnoter, det bliver squ meget langhåret
-
Good, but it would have been nice with a group of only 48 mg
-
Haven‘t they decided on the optimal dose for Glofitamab? They call it step up dosing...
-
Yes sure
-
-
Next steps
While the burning question was whether or not the novel targets are better used before or after BCMA, the more practical solution is to simply combine the mechanisms. In fact, Johnson & Johnson is already at work on that front, with a Phase I study exploring the combination of talquetamab and the BCMA bispecific antibody teclistamab.
-
There’s also preclinical data supporting the role of CD38-targeting agents in T-cell expansion, which suggests that front-line therapy Darzelex (daratumumab) could help potentiate the T-cell engaging effect of antibodies like talquetamab. Accordingly, Johnson & Johnson is also evaluating that combination in a Phase I trial- along with various combinations of teclistamab and pomalidomide- which could represent its best opportunity for leapfrogging the BCMA drug class.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind